IRICoR to present at the 19th Annual International Partnering Conference Bio Europe 2013

IRICoR will be presenting at the upcoming Bio Europe Conference 2013 to be held on November 4 to 6, 2013, Vienna, Austria.

Dr. Steven Klein, Vice-President, Business Development of the Institute for Research in Immunology and Cancer –Commercialization of Research (IRICoR ), a Center of Excellence in Commercialization and Research, will present IRICoR’s Business Model during the 19th Annual International Partnering Conference Bio Europe 2013, in  Vienna, Austria.

This event is Europe’s largest partnering conference which gives to the participants an opportunity to learn about investment trends and meet with leading dealmakers, strategic partners in Life Sciences.

If you would like to arrange a one-on-one meeting with IRICoR’s management team during the conference, please contact Dr. Klein at steven.klein@iricor.ca.

 

About BIO-Europe 2013
The 19th annual BIO-Europe® event will be the largest biotechnology partnering conference held in Europe. Over 3,000 global decision makers from biotechnology, pharma and finance, representing upwards of 1,700 companies from over 50 countries, annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe will take place November 4–6, 2013 in Vienna, Austria.  Pour en savoir plus sur Bio Europe 2013, visitez le site: http://www.ebdgroup.com/bioeurope/index.php

About IRICoR | Institute for Research in Immunology and Cancer – Commercialization of Research
IRICoR is a non-profit organization whose mandate is to accelerate the discovery, development and commercialization of novel drugs that originate from IRIC and Université de Montréal. IRICoR, as a Center of Excellence in Commercialization and Research, invests in highly innovative projects to rapidly transition them from academia to the market, while identifying the best development partners for these commercially-promising projects. For more information about IRICoR, please visit: www.iricor.ca.

 

Information
Steven J. Klein Ph.D., MBA
Vice-President, Business Development
steven.klein@iricor.ca
T +1 514 343.6647

© 2008-2020 IRICoR